June 20, 2016 / 12:37 PM / a year ago

BRIEF-Bellus Health says Kiacta did not meet primary efficacy endpoint in phase 3 study

June 20 (Reuters) - Bellus Health Inc

* Announces top-line phase 3 results of kiacta for treatment of aa amyloidosis

* In study, Kiacta did not meet primary efficacy endpoint in slowing renal function decline

* Kiacta was shown to be safe and well tolerated over treatment periods of greater than 4 years

* Further analysis of data is ongoing. Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below